SPINRAZA
Biological
Biogen, Inc.
Total Payments
$68.5M
Transactions
21,509
Doctors
6,105
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $10.2M | 1,815 | 974 |
| 2023 | $7.4M | 1,875 | 1,185 |
| 2022 | $11.6M | 2,493 | 1,180 |
| 2021 | $6.5M | 2,047 | 1,156 |
| 2020 | $6.4M | 1,161 | 613 |
| 2019 | $7.2M | 3,999 | 1,225 |
| 2018 | $11.8M | 6,272 | 1,364 |
| 2017 | $7.4M | 1,847 | 425 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $59.7M | 2,893 | 87.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.7M | 1,635 | 6.9% |
| Consulting Fee | $2.7M | 711 | 3.9% |
| Travel and Lodging | $802,973 | 3,000 | 1.2% |
| Food and Beverage | $438,834 | 12,238 | 0.6% |
| Royalty or License | $137,000 | 6 | 0.2% |
| Education | $40,840 | 1,024 | 0.1% |
| Grant | $3,800 | 2 | 0.0% |
Payments by Type
Research
$59.7M
2,893 transactions
General
$8.9M
18,616 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies. | Biogen, Inc. | $21.1M | 3 |
| An Open-Label Extension Study for Patients With Spinal Muscular AtrophyWho Previously Participated in Investigational Studies of ISIS 396443 | Biogen, Inc. | $15.3M | 0 |
| A prospective, multi-center, open-label, observational study of the safety, tolerability and effectiveness of SPINRAZA in adults with SMA | Biogen, Inc. | $5.1M | 0 |
| A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy | Biogen, Inc. | $2.7M | 0 |
| A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study with Nusinersen. | Biogen, Inc. | $2.2M | 0 |
| A Phase 4 Study of Nusinersen (BIIB058) Among Patients With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec | Biogen, Inc. | $2.2M | 0 |
| An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy | Biogen, Inc. | $1.9M | 0 |
| A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam | Biogen, Inc. | $1.9M | 1 |
| A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA). | Biogen, Inc. | $1.5M | 1 |
| Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy | Biogen, Inc. | $1.3M | 0 |
| A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec | Biogen, Inc. | $867,291 | 2 |
| Treatment of spinal muscular atrophy with Spinraza (nusinersen) via a novel intrathecal delivery system | Biogen, Inc. | $671,433 | 0 |
| Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy | Biogen, Inc. | $653,400 | 2 |
| SMA Registry Study with the International SMA Consortium (ISMAC) US Network | Biogen, Inc. | $397,546 | 0 |
| Exploring cerebrospinal fluid proteomic and transcriptomic changes in SMA after Spinraza treatment | Biogen, Inc. | $292,368 | 0 |
| Optimizing therapeutics for spinal muscular atrophy | Biogen, Inc. | $276,660 | 0 |
| Nusinersen in Adults with Spinal Muscular Atrophy: An Open Label Study to Assess Efficacy and Exploratory Endpoints | Biogen, Inc. | $233,455 | 0 |
| US-SPN-17-11216 (Elsheikh): Quantifying Motor Unit Response to Nusinersen (Spinraza) in late-onset Spinal Muscular Atrophy(AOP18-376) | Biogen, Inc. | $192,023 | 0 |
| Spinraza (nusinersen) SMA Pregnancy Exposure Study Within Existing SMA Registries | Biogen, Inc. | $161,332 | 0 |
| US-NBS-17-11214: Pilot Newborn Screening Study for SMA in the State of Georgia || AOP18-53 | Biogen, Inc. | $158,099 | 0 |
Top Doctors Receiving Payments for SPINRAZA — Page 245
Ad
Manufacturing Companies
- Biogen, Inc. $68.5M
Product Information
- Type Biological
- Total Payments $68.5M
- Total Doctors 6,105
- Transactions 21,509
About SPINRAZA
SPINRAZA is a biological associated with $68.5M in payments to 6,105 healthcare providers, recorded across 21,509 transactions in the CMS Open Payments database. The primary manufacturer is Biogen, Inc..
Payment data is available from 2017 to 2024. In 2024, $10.2M was paid across 1,815 transactions to 974 doctors.
The most common payment nature for SPINRAZA is "Unspecified" ($59.7M, 87.1% of total).
SPINRAZA is associated with 20 research studies, including "A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies." ($21.1M).